Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
Objective This study aimed to estimate the cost–utility of sofosbuvir/velpatasvir (SOF/VEL) compared with other direct-acting antivirals (DAAs) in Chinese patients with hepatitis C virus (HCV).Design A Markov model was developed to estimate the disease progression of patients with HCV over a lifetim...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/8/e035224.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|